India's Laurus Labs closes lower on fifth straight qtrly profit drop
** Shares of Laurus Labs LAUL.NS close 2% lower to 425.9
rupees
** Co's March-qtr profit fell roughly 26.6% YoY, its fifth
straight quarterly profit drop
** Rival Glenmark Life Sciences GLEM.NS also posted Q4
profit drop on the day; its stock dropped after results
** Analysts' avg rating on LAUL stock is "hold", and is
"buy" on GLEM - LSEG data
** LAUL flips to YTD loss, down 1% so far this year; GLEM up
18% from last year
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Alivus Life Sciences
See all newsBrief: Alivus Life Sciences Incorporates Subsidiary Alivus Life Sciences Do Brasil Ltda In Brazil
Brief: Alivus Life Sciences To Buy 76% Stake In Iqgen-X Pharma For Approx 91.2 Million Rupees
India's Alivus rises to 15-month high as brokerages optimistic about drugmaker's annual outlook
India's Alivus Life Sciences rises after quarterly profit increase
Brief: Alivus Life Sciences Ltd March-Quarter Profit 1.63 Billion Rupees